Search research articles
Contact Us
Filters
Showing results (101-110 of 106) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 106 results.
Frontiers in Immunology
|
September 5, 2022
Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma
Huanxin Zhang, Zhiling Yan, Ying Wang, et al.
Cancer Medicine
|
July 2, 2020
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
Wei Sang, Ming Shi, Jingjing Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2022
Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma
Ying Wang, Jiang Cao, Weiying Gu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2023
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial
Jieyun Xia, Hujun Li, Zhiling Yan, et al.
The Lancet. Haematology
|
April 14, 2025
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial
Jieyun Xia, Qian Sun, Dian Zhou, et al.
Frontiers in Immunology
|
March 7, 2022
A Novel Prognostic Index Model for Adult Hemophagocytic Lymphohistiocytosis: A Multicenter Retrospective Analysis in China
Ziyuan Shen, Yingliang Jin, Qian Sun, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 106) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 106 results.
Frontiers in Immunology
|
September 5, 2022
Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma
Huanxin Zhang, Zhiling Yan, Ying Wang, et al.
Cancer Medicine
|
July 2, 2020
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
Wei Sang, Ming Shi, Jingjing Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2022
Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma
Ying Wang, Jiang Cao, Weiying Gu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2023
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial
Jieyun Xia, Hujun Li, Zhiling Yan, et al.
The Lancet. Haematology
|
April 14, 2025
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial
Jieyun Xia, Qian Sun, Dian Zhou, et al.
Frontiers in Immunology
|
March 7, 2022
A Novel Prognostic Index Model for Adult Hemophagocytic Lymphohistiocytosis: A Multicenter Retrospective Analysis in China
Ziyuan Shen, Yingliang Jin, Qian Sun, et al.
Page
of 11